Samaritan Announces U.S. Patent Allowance Covering PBR Technology.
This United States patent was issued to Georgetown University, research partner and collaborator of Samaritan Pharmaceuticals. Samaritan holds the world-wide exclusive license to this patent and to future issued patents that may be issued in the same patent family.
In addition to securing the above patent protection in United States, the Australian Patent Office issued patent number 772764 in August 2004. Samaritan is also seeking patent protection in Canada, Europe, and Japan. "This patent further expands Samaritan's position in the area of PBR proteins," commented Eugene Boyle, CFO of Samaritan Pharmaceuticals.
Some of the research to date on this patent has been published in the following journals:
Li H, Degenhardt, Tobin D, Yao, Z., Tasken K, Papadopoulos V (2001) Identification, localization, and function in steroidogenesis of PAP7: A peripheral-type benzodiazepine receptor- and protein kinase A (RI(alpha))-associated protein. Molecular Endocrinology, 15:2211-2228.
Liu J, Han Z, Sandrini F, Bei T, Matyakhina L, Stratakis CA, Papadopoulos V (2003) Molecular cloning, chromosomal localization of human peripheral-type benzodiazepine receptor- and PKA regulatory subunit type 1A (PRKAR1A)-associated protein PAP7 and studies in PRKAR1A mutant cells and tissues. FASEB Journal, 17:1189-1191. Full text of this article, go to http://www.fasebj.org/cgi/doi/10.1096/fj.02-1066fje
Liu J, Cavalli LR, Haddad BR, Papadopoulos V (2003) Molecular cloning, genomic organization, chromosomal mapping and sub cellular localization of mouse PAP7: a PBR and PKA-RI(alpha) associated protein. Gene, 308:1-10.
Liu J, Li H, Papadopoulos V (2003) PAP7, a PBR/PKA-RI(alpha)-associated protein: a new element in the relay of the hormonal induction of steroidogenesis. J Steroid Biochemistry & Molecular Biology, 85: 275-283.
Samaritan Pharmaceuticals: "We LIV....to Save Lives."
Samaritan Pharmaceuticals is a drug development company driven to commercialize innovative drugs. Samaritan, in collaboration with Georgetown University, is advancing eight promising compounds, out of its pipeline of 250 possible drug candidates; all of which have the potential to create revenue-generating opportunities. Additional information is at www.samaritanpharma.com.
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements.
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 8, 2005|
|Previous Article:||Pentaho Receives $5 Million in Series A Funding; Investment Further Fuels Pentaho's Leadership in Open Source BI.|
|Next Article:||Quick-Med Technologies, Inc. Receives Key Patent on Its NIMBUS Technology; U.S. Patent Allowance Significantly Strengthens Overall Patent Portfolio.|